Fig. 8

Knockdown of IRE1a diminishes the synergism of Gilteritinib plus ATO combination treatment of FLT3-ITD-mutated cells. a Knockdown of IRE1a in MV4-11 and MOLM13 cells was confirmed by RT-qPCR. Data are shown as mean ± SD. ***P < 0.001. b, c Knockdown of IRE1a in MV4-11 and MOLM13 cells was confirmed by western blot. Data are shown as mean ± SD. ***P < 0.001. d–g Cell apoptosis in MV4-11 and MOLM13 cells with nonsilencing (NS) siRNA or IRE1a-targeted siRNAs following treatment with Gilteritinib (2.5 nM) plus ATO (0.5 µM) for 48 h was detected using flow cytometry. Data are shown as mean ± SD. *P < 0.05, **P < 0.01. h–k Expression of BAX and BCL-2 in MV4-11 and MOLM13 cells with NS siRNA or IRE1a-targeted siRNAs following 48 h treatment with Gilteritinib (2.5 nM) and ATO (0.5 µM) was tested by western blot. Data are shown as mean ± SD. **P < 0.01